Crowdberry launches new investment campaign for Slovak company whose technology enables early cancer detection
29/02/2024
Glycanostics, a Slovak biotechnology company that has developed an innovative and accurate method for early cancer diagnosis, has launched a new investment campaign on the Crowdberry platform as part of a $10 million investment round. It plans to use the growth funds to develop and commercialize its revolutionary cancer diagnosis method, which is based on tracking changes in complex sugars on the surfaces of cells. Investor interest is proving to be considerable.
Glycanostics' patented technology enables early and accurate diagnosis of various cancers from the blood, helping to improve treatment outcomes and save the lives of millions of patients by catching the disease in its early stages. Since the launch of the investment campaign on the Crowdberry platform, more than 100 investors have expressed interest in the €1.5 million fundraising. In addition to supporting a momentous product, the expected annual return in the tens of percent is also proving attractive to investors.
